Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908423 · ClinicalTrials.gov registry record · Phase 4
Xeomin® and Gait Related Mobility After Stroke
A Phase 4 study of Stroke, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04908423 is a Phase 4 study of Stroke that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04908423, a Phase 4 study of Stroke, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).
Conditions Studied
Interventions
- DRUG Xeomin®
Study Locations (1)
North Carolina
- Carolinas Rehabilitation - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908423
The ClinicalTrials.gov registry entry for NCT04908423 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Xeomin® is the first listed.
NCT04908423 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04908423 about?
NCT04908423 is a clinical study titled "Xeomin® and Gait Related Mobility After Stroke". The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabil...
What is the current status of trial NCT04908423?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-10-19. Estimated completion is 2027-04.
What conditions does trial NCT04908423 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT04908423?
The interventions under investigation include: Xeomin® (DRUG).
Who is sponsoring clinical trial NCT04908423?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04908423 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
International Care Bundle Evaluation in Cerebral Hemorrhage Research
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
COMPLETED · Phase 4
-
Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.